Evaluation of waning of IgG antibody responses after rVSVΔG-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccines: a modelling study from the PREVAC randomized trial

rVSVΔG-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo are WHO-prequalified vaccination regimens against Ebola virus disease (EVD). Challenges associated with measuring long-term clinical protection warrant the evaluation of immune response kinetics after vaccination. Data from a large phase 2 randomized doubl...

Descripció completa

Dades bibliogràfiques

Autors principals:	Simon Valayer, Marie Alexandre, Mélanie Prague, Abdoul Habib Beavogui, Seydou Doumbia, Mark Kieh, Brian Greenwood, Bailah Leigh, Marie Poupelin, Christine Schwimmer, Samba O. Sow, Irina Maljkovic Berry, Jens H. Kuhn, Daniela Fusco, Natasha Dubois Cauwelaert, Deborah Watson-Jones, Rodolphe Thiébaut, Yves Lévy, Yazdan Yazdanpanah, Laura Richert, Edouard Lhomme
Format:	Artigo
Idioma:	Inglês
Publicat:	Taylor & Francis Group 2025-12-01
Col·lecció:	Emerging Microbes and Infections
Matèries:	Ebola virus disease vaccine immunogenicity antibody Western Africa modelling
Accés en línia:	https://www.tandfonline.com/doi/10.1080/22221751.2024.2432353
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!